Aza Technology, Inc.

2:00 PM - 3:00 PM (PDT), Wednesday, June 15, 2022
Aza Technology is a startup spun out of Stanford University poised to deliver a point-of-care device targeting diagnosis and management of hyperammonemia, which is responsible for a host of neurotoxic effects seen in Urea Cycle Disorder (UCD) and organic acidemia (OA) patients. Hyperammonemia is also a root cause of hepatic encephalopathy, a serious condition that occurs secondary to alcoholic and non-alcoholic cirrhosis (NASH), resulting in over $2 billion in hospitalizations in the US alone.
Our foundational intellectual property enables a home-use and point-of-care diagnostic device for evaluation of blood ammonia levels. In concert with their physicians, end-users will be able to treat their own ammonia elevations with their choice of several safe and effective therapeutics. Our product will allow parents of UCD and OA patients to monitor their child’s ammonia status and adequately manage their disease without continual, costly, and cumbersome interventions by emergency rooms and doctors’ offices. Additionally, better treatment resulting from the use of our product will reduce the incidence of hepatic encephalopathy in the 5 million patients at high risk in the US, representing a significant cost-savings to insurers and an improved quality of life to patients.
President and CTO
Aza Technology, Inc.